Zurcher Kantonalbank Zurich Cantonalbank Sells 19,021 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 80.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,576 shares of the exchange traded fund’s stock after selling 19,021 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in SPDR S&P Biotech ETF were worth $386,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bearing Point Capital LLC raised its position in SPDR S&P Biotech ETF by 1.9% in the 1st quarter. Bearing Point Capital LLC now owns 59,155 shares of the exchange traded fund’s stock worth $4,797,000 after purchasing an additional 1,131 shares during the last quarter. Nvwm LLC raised its position in SPDR S&P Biotech ETF by 11.4% in the 1st quarter. Nvwm LLC now owns 13,173 shares of the exchange traded fund’s stock worth $1,068,000 after purchasing an additional 1,344 shares during the last quarter. First Heartland Consultants Inc. raised its position in SPDR S&P Biotech ETF by 2.7% in the 1st quarter. First Heartland Consultants Inc. now owns 6,344 shares of the exchange traded fund’s stock worth $514,000 after purchasing an additional 168 shares during the last quarter. Cetera Investment Advisers raised its position in SPDR S&P Biotech ETF by 3.8% in the 1st quarter. Cetera Investment Advisers now owns 154,330 shares of the exchange traded fund’s stock worth $12,516,000 after purchasing an additional 5,604 shares during the last quarter. Finally, Garrison Bradford & Associates Inc. bought a new position in SPDR S&P Biotech ETF in the 1st quarter worth approximately $39,000.

SPDR S&P Biotech ETF Price Performance

XBI stock opened at $85.43 on Friday. The company has a 50 day moving average price of $85.00 and a 200 day moving average price of $84.17. The stock has a market capitalization of $4.63 billion, a PE ratio of 11.47 and a beta of 0.97. SPDR S&P Biotech ETF has a fifty-two week low of $66.66 and a fifty-two week high of $105.47.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Stories

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.